¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Crit Rev Ther Drug Carrier Syst"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® carrier ÇÑ±Û º¸±ÕÀÚ, º¸ÃæÀÚ, º¸ÀÎÀÚ, ³ª¸£°³
¼³¸í   
  1. Áõ»ó¾øÀ̠ü³»¿¡ º´¿ø¹Ì»ý¹°ÀÌ Á¸ÀçÇÏ¿© °¨¿°ÀüÆÄÀÚÀÇ ¿ªÇÒÀ» Çϴ °³Ã¼. ÀÌ·¯ÇÑ °³Ã¼¸¦ º¸±Õ»óÅÂ(carrier state)¶ó ºÎ¸£°í ÀÖ´Ù. 2. ³ª¸£°³. ¼¼Æ÷³»ÀÇ ¹°Áú·Î¼­ ÇѰ³ ¶Ç´Â µÎ°³ÀÇ ÀüÀÚ¸¦ ¹Þ¾Æ È¯¿øµÇ³ª ±× ÈÄ ´Ù½Ã »êÈ­µÉ ¼ö Àִ °Í. 3. º¸ÀÎÀÚ. º¸Åë¿°»öü¼ºÀ̵砼º¿°»öü¼ºÀ̵砰£¿¡ ±× Á¤»óÀÇ ´ë¸³À¯ÀüÀÚ¿Í ´õºÒ¾î ¿­¼ºÀ¯ÀüÀÚ¸¦ º¸À¯Çϴ °³Ã¼. 4. ¹æ»ç¼±Çп¡¼­ ´Ù¸¥ ¹°Áú ÃßÀûÀÚ¿Í °°ÀÌ »ç¿ëµÇ¸ç, È­ÇÐÀû ¹°¸®Àû ÀÛ¿ëÀ¸·Î ±× ÃßÀûÀÚ¸¦ ¿î¹ÝÇϴ ¹°Áú. 5. ¼¼Æ÷³»¸·À» ÅëÇÑ ¿î¼ÛÀÇ °æ¿ì¿Í °°ÀÌ ¾î¶² ¹°ÁúÀÌ °¡¿ª¼ºÀ¸·Î ºÎÂøÇϴ ºÐÀÚ.
¿µ¹® antihypertensive drug ÇÑ±Û °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
¼³¸í   
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇϸ砳ôÀº Ç÷¾ÐÀ» ³·Ãߴ ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃ۴ Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀǠȰµ¿À» ¾îµð¼±°¡ Â÷´ÜÇϴ ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù.
¿µ¹® antimalarial drug ÇÑ±Û ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
¼³¸í   
  ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Å°´Ï³×, Å¬·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼­ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼­ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ À־ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼­ÀǠȯ»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇϴ °Í(Ç×¹ø½Äü ¾àÀº Å¬·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Å¬·Î·Î±¸¾Æ³ªÀ̵å, Å°´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦Çϴ °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×À̴ °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇѠŸÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ È¯ÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯È­ÇÏÁö ¾Ê´Â´Ù.
¿µ¹® drug ÇÑ±Û ¾à, ¾à¹°, ¾àÁ¦
¼³¸í   
  1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½Ã۴ °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â È­ÇÕ¹°. ¾à¸®Çп¡¼­´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â È­Çй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °­ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼­·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ­, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, Ã¼Áß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ­´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í Àִ ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à.
¿µ¹® drug resistance ÇÑ±Û ¾à¹°³»¼º
¼³¸í   
  1. È­Çпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ È­Çпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼­ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈ­µÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ Àִ ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ Àִ ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇϸ頳»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼­ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇϴ °Í µîÀÌ ±× ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • asymptomatic carrier
    ¹«Áõ»óº¸±ÕÀÚ
  • amalgam carrier
    ¾Æ¸»°¨³ª¸£°³, ¾Æ¸»°¨¿î¹Ýü
  • constant carrier
    °è¼Óº¸±ÕÀÚ
  • convalescent carrier
    ȸº¹±âº¸±ÕÀÚ
  • cyst carrier
    ³¶º¸ÃæÀÚ
  • carrier
    1. º¸±ÕÀÚ, º¸ÃæÀÚ 2. º¸ÀÎÀÚ 3. ³ª¸£°³, ¿î¹Ýü
  • carrier determinant
    ¿î¹Ýü°áÁ¤ÀÎÀÚ
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carrier mediated transport
    ¿î¹Ýü¸Å°³¿î¹Ý
  • carrier protein
    ¿î¹Ý´Ü¹éÁú
  • carrier state
    º¸±Õ»óÅÂ
  • electron carrier
    ÀüÀÚ¿î¹Ýü
  • healthy carrier
    °Ç°­º¸±ÕÀÚ
  • hemophiliac carrier
    Ç÷¿ìº´º¸ÀÎÀÚ
  • heterozygous carrier
    ÀÌÁ¾Á¢ÇÕº¸ÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier
    º¸±ÕÀÚ, º¸ÃæÀÚ, º¸ÀÎÀÚ, ³ª¸£°³, ¿î¹Ýü
  • heterozygous carrier
    ÀÌÁ¾Á¢ÇÕº¸ÀÎÀÚ
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antiemetic drug
    ±¸Åä¾à, Ç×±¸ÅäÁ¦
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
  • antihypertensive drug
    °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
  • antimalarial drug
    ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amalgam carrier
    ¾Æ¸»°¨³ª¸£°³, ¾Æ¸»°¨¿î¹Ýü
  • asymptomatic carrier
    ¹«Áõ»óº¸±ÕÀÚ
  • carrier
    º¸±ÕÀÚ, º¸ÃæÀÚ, º¸ÀÎÀÚ, ³ª¸£°³
  • carrier determinant
    ¿î¹Ýü°áÁ¤±â
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carrier protein
    ¿î¹Ý´Ü¹é, ¿î¹Ý´Ü¹éÁú
  • carrier specificity
    ³ª¸£°³Æ¯À̼º, ¸Å°³Æ¯À̼º, ¿î¹ÝüƯÀ̼º
  • carrier state
    º¸±Õ»óÅÂ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³¿î¹Ý
  • constant carrier
    °è¼Óº¸±ÕÀÚ
  • convalescent carrier
    ȸº¹±âº¸±ÕÀÚ
  • cyst carrier
    ³¶º¸ÃæÀÚ
  • electron carrier
    ÀüÀÚ¿î¹Ýü
  • healthy carrier
    °Ç°­º¸±ÕÀÚ
  • hemophiliac carrier
    Ç÷¿ìº´º¸ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • OTC drug : over-the-counter drug
    ÀϹݸžà.
  • amalgam carrier
    ¾Æ¸»°¨¼ö¼Û±â(¡­âÃáêÐï).
  • healthy carrier
    °Ç°­º¸±ÕÀÚ(ÊÙËÓË»Ëö). ±â»ý°Ç°­º¸ÃæÀÚ(ÊÙËÓ̧Ëö).
  • hemophiliac carrier
    Ç÷¿ìº´ÀÎÀÚº¸À¯ÀÚ.
  • hemophiliac carrier
    Ç÷¿ìº´ÀÎÀÚº¸À¯ÀÚ.
  • hepatitis,carrier state
    º¸±ÕÀÚ(ÜÁжíº)
  • heterozygous carrier
    ÀÌÁ¾Á¢ÇÕº¸À¯ÀÚ.
  • hod carrier s palsy
    Àâ¿ë ¿î¹ÝÀÚ ¸¶ºñ(íÚéÄê¡Úæíº Ýö).
  • hod carrier s palsy
    Àâ¿ë¿î¹ÝÀÚ¸¶ºñ(íÚéÄê¡Úæíº Ýö).
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • IND : investigational new drug
    ½ÃÇè¿ë½Å¾à.
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • NDA : new drug application
    ½Å¾àÇã°¡½Åû.
  • TDM : therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ ¸ð´ÏÅ͸µ.
  • addiction, drug
    ¸¶¾à»ó½À(ئå·ßÈã§)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug dependence ; drug dependency
    ¾à¹°ÀÇÁ¸(¼º).
  • amalgam carrier
    ¾Æ¸»°¨¼ö¼Û±â(¡­âÃáêÐï).
  • asymptomatic carrier
    ¹«Áõ»óº¸±ÕÀÚ.
  • bacillus carrier
    ¼¼±Õº¸±ÕÀÚ(á¬Ð¶ÜÁжíº).
  • bacteria carrier
    ¼¼±Õº¸±ÕÀÚ.
  • carrier
    ¹Ý¼ÛÆÄ, ij¸®¾î
  • carrier
    º¸±ÕÀÚ, ¿î¹Ýü, ´ãü
  • carrier
    ¿î¹Ýü(ê¡Úæô÷)
  • carrier determinant
    ¿î¹Ýü °áÁ¤±â
  • carrier effect
    ¿î¹Ýü È¿°ú
  • carrier mediated diffusion
    ´ãü(¸Å°³) È®»ê.
  • carrier mediated transport
    ¿î¹Ýü¸Å°³ À̵¿
  • carrier prophylactic
    ij¸®¾î¿¹¹æÁ¦.
  • carrier protein
    ¿î¹Ý´Ü¹éÁú
  • carrier protein
    ¿î¹Ý´Ü¹é(¡­Ó±ÛÜ)
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antiamebic drug
    ¾Æ¸Þ¹Ù±¸ÃæÁ¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
  • carrier
    º¸ÃæÀÚ
  • convalescent carrier
    ȸº¹±âº¸ÃæÀÚ
  • healthy carrier
    °Ç°­º¸ÃæÀÚ
  • permanent carrier
    ¿µ±¸º¸ÃæÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • drug-detoxication enzyme
    ¾à¹°Çص¶ È¿¼Ò(å·Úªú°Ô¸ý£áÈ) (ÔÒ) drug-metabolizing enzyme
  • drug-metbolizing enzyme
    ¾à¹°´ë»ç È¿¼Ò(å·ÚªÓÛÞóý£áÈ)
  • drug resistance
    ¾à¹° ÀúÇ×(å·Úªî½ù÷)
  • drug-resistance plasmid
    ¾à¹°ÀúÇ×(å·Úªî½ù÷) Çö󽺹̵å (ÔÒ) R plasmid
  • narcotic drug
    ¸¶¾à(ئå·)
  • psychedelic drug
    ȯ°¢Á¦(ü³ÊÆð¥)
  • radiomimetic drug
    ¹æ»ç¼± ¾ç(À¯»ç) ¾à¹°(Û¯ÞÒàÊåÆ(ëºÞÄ)å·Úª)
  • sulfa drug
    ¼³ÆÄÁ¦(ð¥)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
  • ATP-ADP carrier
    ATP-ADP ¿î¹Ýü(ê¡Úõô÷)
  • biotin carboxyl carrier protein
    ¹ÙÀÌ¿Àƾ Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • carboxyl carrier protein
    Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • carrier
    "ij¸®¾î, ¿î¹Ýü(ê¡Úæô÷)"
  • carrier ampholyte
    ij¸®¾î ¾ç¼ºÀüÇØÁú(Õ×àõï³ú°òõ)
  • carrier displacement chromatography
    ij¸®¾î ġȯ(öÇüµ) Å©·Î¸¶Åä±×·¡ÇÇ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier
    ¹Ý¼ÛÆÄ, ij¸®¾î, º¸À¯ÀÚ, º¸±ÕÀÚ, ´ãü
  • healthy carrier
    °Ç°­º¸±ÕÀÚ, °Ç°­º¸ÃæÀÚ
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • drug abuse
    ¾à¹°³²¿ë
  • narcotic drug
    ¸¶¾à
  • tuberculostatic drug
    Ç×°áÇÙ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Crit, crit critical; hematocrit
syst system, systemic; systole, systolic
SYST-EUR Systolic Hypertension in Europeans Study
DA dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis...
REV reticuloendotheliosis virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SYST-EUR Systolic Hypertension in Europe
RRE REV response element
REV Reticuloendotheliosis virus
REV-T Reticuloendotheliosis virus strain T
RRE Rev Responsive Element
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 2853
    JournalTitle: Critical reviews in therapeutic drug carrier systems.
    MedAbbr: Crit Rev Ther Drug Carrier Syst
    ISSN: 0743-4863
    ESSN:
    IsoAbbr:
    NlmId: 8511159
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • amalgam carrier
    ¾Æ¸»°¨ ¼ö¼Û±â
    ¹°··¹°··ÇÑ ¾Æ¸»°¨À» »èÁ¦ÇÑ ¿Íµ¿À̳ª Ʋ ¼ÓÀ¸·Î ¿î¹ÝÇϴµ¥ »ç¿ëÇÏ´Â µµ±¸.
  • bacteria carrier
    ¼¼±Õ º¸±ÕÀÚ
  • carrier
    º¸±ÕÀÚ, ij¸®¾î, º¸À¯ÀÚ, ´ãü, º¸Çè¾÷ÀÚ
    1. ÁúȯÀÇ ÀÓ»ó ¼Ò°ßÀº ¾øÀÌ Æ¯º°ÇÑ °¨¿° ÀÎÀÚ¸¦ °¡Áö°í ´Ù¸¥ »ç¶÷À» °¨¿°½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ´Â »ç¶÷. °Ç°­Çϰųª ȸº¹±â¿¡ ÀÖ´Â º¸±ÕÀÚÀÏ ¼ö ÀÖ´Ù. 2. Á¦±âµÈ ÀÌÀǸ¦ ÇØ°áÇØ Áְųª Ä¡·á¸¦ Á¦°øÇϱâ·Î µ¿ÀÇÇÑ Ä¡°ú Ä¡·á °è¾àÀÚ Ãø.
  • carrier mediated transport
    ¿î¹Ýü ¸Å°³ À̵¿
  • carrier specificity
    ¿î¹Ýü ƯÀ̼º
  • chronic carrier
    ¸¸¼º º¸±ÕÀÚ
  • electron carrier
    ÀüÀÚ ¿î¹Ýü
  • foil carrier
    ±Ý¹Ú ¼ö¼Û±â
    foil
  • healthy carrier
    °Ç°­ º¸±ÕÀÚ, °Ç°­ º¸ÃæÀÚ
    Áõ»óÀÌ ¾øÀ¸¸é¼­ ±ÕÀ» °¡Áö°í ÀÖ´Â »ç¶÷.
  • oxygen carrier
    »ê¼Ò ¿î¹Ýü
  • permanent carrier
    ¿µ±¸ º¸±ÕÀÚ, ¿µ±¸ º¸ÃæÀÚ
  • radiation carrier
    ¹æ»ç¼± °ø±Þ ÀåÄ¡
  • radioisotope seed carrier ±¸°­¾Ï Áß °æ, ¿¬±¸°³ ¾ÏÁ¾¿¡¼­´Â ·¹ÁøÀ¸·Î ±³ÇÕÀåÄ¡¸¦ ¸¸µé¾î ¹æ»ç¼± ¹°ÁúÀ» Æ÷¸Å½ÃÄÑ ±ÙÁ¢ Á¶»ç¸¦ ½ÃÇàÇϱ⵵ Çϴµ¥ ÀÌ·± ÀåÄ¡¸¦ Radioisotope seed carrier¶ó°í ÇÑ´Ù.

    radioisotope vesicoureteral reflex test

    ¹æ»ç¼± µ¿À§ ¿ø¼Ò¼º ¹æ±¤ ¿ä°ü ¿ª·ù ½ÃÇè
  • transitory carrier
    Àϰú¼º º¸±ÕÀÚ
  • addicting drug
    ½À°ü¼º ¾à
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
gene products, rev Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion.
(12 Dec 1998)
genes, rev DNA sequences that form the coding region for a protein that regulates the expression of the viral structural and regulatory proteins in human immunodeficiency virus (HIV). Rev is short for regulator of virion.
(12 Dec 1998)
rev <molecular biology> A regulatory protein produced by HIV within infected cells. Rev helps transport HIV RNA sequences (messenger RNA) out from the nucleus into the cells cytoplasm, where it directs construction of proteins for new virus particles.
(11 Jan 1998)
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
acetoacetyl-acyl carrier protein synthase <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin
Registry number: EC 2.3.1.-
Synonym: acetoacetyl-acp synthase
(26 Jun 1999)
acyl-(acyl-carrier-protein)-phospholipid acyltransferase <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine
Registry number: EC 2.3.1.40
Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase
(26 Jun 1999)
acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source
Registry number: EC 2.3.1.129
Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein
(26 Jun 1999)
acyl carrier protein <protein> A small (77 peptides long) protein which binds six other enzymes involved in fatty acid synthesis. It was first isolated in E. Coli bacteria.
(09 Oct 1997)
acyl carrier protein acylase <enzyme> From E coli
Registry number: EC 2.3.1.-
Synonym: acp acylase
(26 Jun 1999)
amalgam carrier An instrument used to transport triturated amalgam to a cavity preparation and to deposit it therein.
(05 Mar 2000)
beta-hydroxyacyl-(acyl-carrier-protein)dehydrase <enzyme> In fatty acid synthesis; specific for acyl carrier protein; cannot use acyl CoA; see also faba gene product
Registry number: EC 4.2.1.-
Synonym: beta-ohacyl-acp dehydrase, beta-hydroxyacyl-acyl carrier protein dehydratase, fabz gene product
(26 Jun 1999)
galactose-diphosphoglycosyl carrier lipid synthetase <enzyme> Catalyses synthesis of gcl-pp-gal from udp gal and p-gcl; also catalyses exchange between the uridylyl moiety of udpgal and ump
Registry number: EC 2.4.1.-
(26 Jun 1999)
malonyl-CoA-acetyl CoA-acyl carrier protein S-acyltransferase <enzyme> Specific for either malonyl-CoA or acetyl-CoA; a component of fatty acid synthase
Registry number: EC 2.8.3.-
Synonym: mcoa-acoa acp acyltransferase
(26 Jun 1999)
manifesting carrier An organism heterozygous for what is ordinarily a recessive condition which, as a result of special mechanisms (such as lyonization, allelic exclusion, or a deletion in the homologous chromosome), has phenotypic manifestations.
Synonym: manifesting carrier.
(05 Mar 2000)
genetic carrier An unaffected heterozygote bearing a usually harmful recessive gene, a cancer that bears a dominant but latent age-dependent trait to have offspring with unbalanced karyotypes.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • crit
    critic(al);criticism;criticized
  • REV
    reentry vehicle Àçµ¹ÀÔ ºñ»óü
  • Rev
    ...¸ñ»ç(½ÅºÎ)´Ô(¼ºÁ÷ÀÚ¿¡ ´ëÇÑ °æÄª)
  • Rev.
    Revelation;Reverend
  • Rev. Ver.
    Revised Version (of the Bible)
  • Rt.Rev(d).
    Right Reverend Rts.rights R.T.S. Religious Tract SocietyÁ¾±³ Ã¥ÀÚ Çùȸ(U.S.C.L.¿¡ ÅëÇÕ);r-t-w ready-to-wear;Ru ruthenium;R.U. rat unit;Áã ´ÜÀ§;Rugby Union
  • rev
    (³»¿¬±â°üµîÀÇ)ȸÀü;(³»¿¬±â°üµîÀÇ)ȸÀü¼Óµµ¸¦ ¿Ã¸®´Ù;(»ý»ê·ÂÀ»)Áõ°¡½ÃŰ´Ù;°í¼ÓÀ¸·Î ¿îÀü(Á¶¾÷)ÇÏ´Ù;º¸´Ù ´õ Ȱµ¿ÀûÀ¸·Î ÇÏ´Ù;(¿£ÁøÀÌ)ȸÀüÇÏ´Ù;(³»¿¬±â°üµîÀÌ)ȸÀü¼Óµµ°¡ »¡¶óÁö´Ù;Ȱµ¿ÀûÀÌ µÇ´Ù;¿îµ¿·®ÀÌ Áõ°¡ÇÏ´Ù
  • rev counter
    =TACHOMETER
  • rev.
    revenue;reverse(d);review(ed);revise(d);revision;revolution;revolving
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • combination drug
    º¹ÇÕ¾à(2Á¾ ÀÌ»óÀÇ Ç×»ý ¹°Áú µîÀÇ È¥ÇÕ¾à)
  • counter drug
    ÀÇ»çÀÇ Ã³¹æ ¾øÀÌ ÆÇ¸ÅµÇ´Â ¾à
  • drug
    ¾à;¾àÁ¦;¾àǰ;¸¶¾à;~¿¡ ¾àÀ»³Ö´Ù;¸¶Ãë½ÃŰ´Ù;¹°¸®°ÔÇÏ´Ù
  • drug addict
    ¸¶¾à Áßµ¶ÀÚ
  • drug buster
    (¹Ì)¸¶¾à ´Ü¼Ó°ü 
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á